12 October 2018
Bionure, a biotech company specialized in neuroprotection member of CataloniaBio & HealthTech, announces the appointment of Dr. Laurent Nguyen as the new CEO and strengthens its scientific team with the arrival of Dr. Amit Bar-Or, a multiple sclerosis specialist.
Nguyen is doctor in Medicine and has a solid experience in the pharmaceutical industry at Hoechst-Roussel, Merck, F. Hoffmann-La Roche and Pierre Fabre. He then moved to the biotech sector where he became CEO of a French academic spin-off that he developed into a publicly traded clinical biotech company.
The ongoing Phase I clinical trial of its neuroprotective and remyelinating compound ...
11 October 2018
Alta Life Sciences, the fund led by Guy Nohra, Montserrat Vendrell, Miguel Valls and Scott Moonly and a CataloniaBio & HealthTech member, has led a €3-million round of investment in Mediktor. The round also included Dutch fund Castel Capital and French Naos Capital Partners.
Mediktor is a symptom assessment software launched as a free app in 2014. Over this time, it has done more than 2 million evaluations of symptoms in 150 countries and created a database that can recognise roughly 750 diseases, covering 90% of the cases seen in emergency and primary care. Recently, Mediktor has collaborated with Hospital ...
11 October 2018
Institut Marquès, a global benchmark in gynaecology, obstetrics and assisted reproduction with its main headquarters in Barcelona, has opened a new facility in the modern Beacon Court medical services centre in Sandyford (Ireland). The city of Sandyford is well connected to the centre of Dublin, where the clinic has a surgery for medical appointments.
Created by generations of gynaecologists, InstitutMarquès became a member of CataloniaBio & HealthTech in 2018 and has a scientific division led by Dr Alex Garcia-Faura that is working on several lines of research.
The centre has the latest technology, such as the most modern genetic analysis ...
10 October 2018
Pangaea Oncology, associada a CataloniaBio & HealthTech, ha nomenat Alejandro García Moncayo nou director general corporatiu de la companyia.
García Moncayo és llicenciat en Administració i Direcció d'Empreses per la Universitat Pompeu Fabra i ha cursat un Programa de Desenvolupament Directiu (PDD) a Iese i un màster de Finances corporatives a Esade. Amb més d'11 anys d'experiencia, ha treballat en empreses com AB-Biotics o Renta Corporación. El directiu qualifica el projecte "d'ambiciós i molt interessant".
Fundada a Barcelona el 2007, Pangea Oncology és una companyia de serveis mèdics centrada en l'oncologia de precisió a través de la divisió d'atenció ...
8 October 2018
CataloniaBio & HealthTech has launched a Regulatory Affairs Workgroup (WG) in order to help members stay up-to-date on regulatory changes and implementations, boost institutional relations with agencies, foster the transfer of expertise and know-how to start-ups, and give companies the chance to express their concerns, propose activities and participate in carrying them out.
This WG is coordinated by Lidia Cánovas (Asphalion) and Lluís Chico (NEOS Surgery), both of which are board members, with support from Melqui Calzado (secretary general). "We hope members will participate actively to make this a quality WG that is useful to all," highlighted the coordinating ...
26 September 2018
Ysios Capital, venture capital firm specialised in life sciences and member of CataloniaBio & HealthTech, announced that it has appointed Guillem Laporta as Principal and Claudia D’Augusta and Lance Berman as new Venture Partners to strengthen the strategic area and analysis, as well as international projection.
Laporta started his career at Caixa Capital Risc. Since 2013 was Associate at Edmond de Rothschild group (now Andera Partners).
D'Augusta has an extensive experience in the financial management of biotechnology companies and currently is General Manager at TiGenix. Prior to joining Ysios, Berman was CMO and Senior Vice President at Relypsa in ...
26 September 2018
Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases member of CataloniaBio & HealthTech, today announces the completion of a Series B funding round of €21.3 million, the most important in the Catalan biotechnology sector so far this year.
The funding round was led by Fund+, joined by SRIW, SFPI-FPIM and Sambrinvest, in addition to all Series A investors (Ysios Capital, Kurma Partners, Roche Venture Fund, Idinvest Partners, Chiesi Ventures, Caixa Capital Risc and HealthEquity).
“The proceeds of the round will allow the company to demonstrate the potential of MIN-102 in new indications,” ...
19 September 2018
4 Clinical Trials and Anagram announces their merge with the aim to be the first CRO that integrates Imaging Core Lab services with clinical trial management in Spain.
4 Clinical Trials was born in 2016 to provide support to the clinical reach world from different angles and works in partnership with IEC, a imaging CRO that provides integrated image management solutions for clinical trials.
On the other hand, Anagram, founded in 1998, has a solid track record in supporting clinical trials, both with investigational products and medical devices. With deep experience in cardiovascular and stroke, among other therapeutic areas, Anagram ...
19 September 2018
Avinent and the Institute for Bioengineering of Catalonia (IBEC), members of CataloniaBio & HealthTech, have managed to print 3D prostheses that are incorporated into the body and become their own after about three years.
It is a disruptive innovation in the fields of regenerative medicine and dentistry that will allow to improve treatments for several diseases.
The research project has been carried out for now on a chicken embryo membrane and mice. The 3D bioprinter that is used is one of the few providing the level of precision and features required in regenerative medicine in southern Europe.
Avinent, managed by ...
19 September 2018
Spherium Biomed, specialized in developing biomedical products developed in academia and a member of CataloniaBio & HealthTech, has presented the positive results of the Phase II clinical trial of an innovative treatment for atopic dermatitis at the European Academy of Dermatology and Venerology Congress in Paris.
This is Spherium’s fourth pharmaceutical product in clinical stages and the third to pass the Phase II efficacy studies. The Cyclatop global market is in the 6 billion dollar range worldwide, with an estimated target population of 54 million people for the next decade.
According Luis Ruiz-Ávila, CEO of the biopharmaceutical company: "The next ...
18 September 2018
The Government of Catalonia has set up its Health Advisory Council, whose mission is to provide Minister Alba Vergés with its expert advice in defining the country’s health model for the forthcoming years.
The Council is presided over by Manel Balcells, currently the director of the CIMTI and the health commissioner of Leitat. It also includes renowned professionals in the fields of healthcare, medicine, society and economics, such as Pere Joan Cardona, director of the Experimental Tuberculosis Unit at the Germans Trias i Pujol Health Sciences Research Institute and cofounder of the company Manremyc, which is associated with CataloniaBio & ...
17 September 2018
The company Sibelmed, member of CataloniaBio & HealthTech, has begun to commercialise the spirometer Datospir AIRA and the posture therapy device Somnibel.
"They are two products designed and manufactured according to the latest market trends”, says Albert Grau, sales director of the company.
Datospir AIRA is the only spirometer equipped with Bluetooth technology, and it comes in three models (single-use, Turbine and Fleisch). Likewise, Somnibel is a small, lightweight class-IIa device which attaches to the forehead as the patient sleeps and helps lower the incidence of sleep apnea and positional snoring.
Sibelmed was created in Barcelona in 1980 and ...
15 September 2018
The company Ability Pharma, member of CataloniaBio & HealthTech, has just launched a round of investment of one million euros via the crowdfunding platform Capital Cell in order to continue development of a drug that eliminates cancerous cells.
The goal of the project is to turn cancer, the second leading cause of death in the world, into a chronic illness and thus forestall the death of cancer sufferers. The drug ABTL0812 is administered in combination with chemotherapy in order to augment the response to treatment, and afterward it is administered by itself to prevent relapses.
"We want to give small ...
7 September 2018
Mimetis Biomaterials, a bone regeneration company member of CataloniaBio & HealthTech, has initiated an investment round of 2 million euros which will be raised in two phases. It is hoped to secure around 120,000 euros in the seed capital round through crowdfunding and the rest through a Series A round.
The materials manufactured by Mimetis, a company based in the Vallès Technology Park, facilitate the biological processes that regenerate the lost bone of the patient and can be applied in the dental, craniomaxillofacial and orthopaedic fields. Mimetis’ greatest achievement, however, has been 3D-printed custom implants.
The company previously closed ...
7 September 2018
Prof. Lina Badimon, director of the ICCC programme of the Sant Pau Biomedical Research Institute and co-founder of the spin-off Glycardial Diagnostics, has been appointed Chair of the Advocacy Committee and Board Member of the European Society of Cardiology (ESC). Badimon will hold the position until 2020.
The ESC represents more than 90,000 cardiology professionals around the world and supports the development of policies for the prevention of cardiovascular disease in the European Union, through the European Heart Agency in Brussels.
1 August 2018
The CataloniaBio & HealthTech website (cataloniabio.org) has received more than 96,000 visits during first half of 2018, 68% of Spain and 32% international.
Communication is a strategic focal point for the association, which has several channels aimed at members and stakeholders (investors, entrepeneurs, researchers, journalists...). These channels are the website, social media (more than 25,000 followers on Twitter and LinkedIn and 1,900 views on YouTube), the newsletter with corporate and member news (monthly), the paper review (delivered at the CataloniaBioHT Gala Dinner and BBQ) and internal communications called Weekly Bullets.
On the other hand ...
25 July 2018
Jordi Naval is the new CEO of Biocat, an organisation created in 2006 by the Government of Catalonia to promote the healthcare and life sciences ecosystem along with other actors such as ACCIÓ and the association of companies CataloniaBio & HealthTech.
He is now taking over the position that was left vacant a year ago by the previous CEO Albert Barberà, current Director General for Research and Innovation in Health.
Jordi Naval has a degree in Pharmacy from the University of Barcelona (UB) and in Biochemistry from the Autonomous University of Barcelona (UAB). He has helped launch several start-ups like ...
25 July 2018
The Research Centre for Biomedical Engineering (CREB) of the Polytechnic University of Catalonia (UPC), a CataloniaBio & HealthTech member, inaugurated its new facilities on 6 July with a day of conferences and visits from researchers and members of the UPC governing bodies.
Most of the research groups at the CREB have moved to the offices and laboratories on the fourth floor at the Barcelona School of Industrial Engineering. Previously, they were located in several different buildings at the university.
The CREB has more than 25 years of experience in technology transfer, holds 27 patents and 5 to out-license, and has ...
25 July 2018
Devicare, member of CataloniaBio & HealthTech, is moving forward in its international expansion by closing licensing and distribution agreements in Argentina, Uruguay and Peru. Various pharmaceutical companies will introduce the products from the Lit-Control® brand to improve the urinary healthcare of the residents of Latin America. The company had previously announced its entry into Mexico and Colombia.
“These agreements with leading urological pharmaceutical companies confirm our scientific work, our clinical data, as well as the commercial interest in our products” remarks Rosendo Garganta, co-Founder and CEO of the company located at the UAB Research Park.
The company expects to end ...
23 July 2018
German multinational corporation Hartmann, a CataloniaBio & HealthTech member, will invest €10 million between 2019 and 2021 in its two plants in Mataró and Montornès del Vallès (Barcelona), according to financial newspaper Expansión.
The Mataró factory is a global benchmark in developing and manufacturing adhesive healthcare products and is currently responsible for production of the company’s popular plasters.
In 2017, Hartmann acquired the Lindor brand from Procter & Gamble and saw revenue of €175 million in Spain, up 52% from 2016. The company is open to new acquisitions to continue growing in Spain and expects to see sales of €250 ...